In rat models of knee OA, the use of a GLP-1 agonist reduced joint inflammation and cartilaginous degradation [69,70], thus highlighting GLP-1 analogues as worthy of further investigation in MetS-OA. This evidence concerns the gene GLP1R and metabolic syndrome.